Shares of Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of C$1.40 and traded as high as C$1.42. Oncolytics Biotech shares last traded at C$1.41, with a volume of 199,488 shares.
Analyst Upgrades and Downgrades
Separately, Raymond James upgraded Oncolytics Biotech to a "moderate buy" rating in a research note on Thursday, November 14th.
Get Our Latest Analysis on ONC
Oncolytics Biotech Stock Performance
The company's fifty day moving average price is C$1.42 and its two-hundred day moving average price is C$1.40. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The firm has a market capitalization of C$109.91 million, a PE ratio of -3.76 and a beta of 1.35.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Articles
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
